Trial Profile

A phase IIa trial of Isomyosamine in elderly patients with sarcopenia

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 05 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Isomyosamine (Primary)
Indications Sarcopenia
Focus Therapeutic Use
Sponsors TNF Pharmaceuticals

Most Recent Events

05 Apr 2025 New trial record
17 Mar 2025 Results presented in a TNF Pharmaceuticals media release
17 Mar 2025 According to TNF Pharmaceuticals media release, company announced that data from Phase 2a clinical trial of isomyosamine was presented last week in a podium session at the peer-reviewed 15th International Conference on Frailty and Sarcopenia Research (ICFSR) held March 12-14, 2025, in Toulouse, France.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com